VIVOS THERAPEUTICS INC (VVOS) Stock Fundamental Analysis
USA - NASDAQ:VVOS - US92859E2072 - Common Stock
2.36 USD
-0.11 (-4.45%)
2.35 USD
-0.01 (-0.42%)
Taking everything into account, VVOS scores 2 out of 10 in our fundamental rating. VVOS was compared to 100 industry peers in the Health Care Providers & Services industry. VVOS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VVOS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VVOS had negative earnings in the past year.
In the past year VVOS has reported a negative cash flow from operations.
In the past 5 years VVOS always reported negative net income.
In the past 5 years VVOS always reported negative operating cash flow.
1.2 Ratios
VVOS has a worse Return On Assets (-55.01%) than 91.00% of its industry peers.
With a Return On Equity value of -312.46%, VVOS is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -312.46% | ||
| ROIC | N/A |
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 55.93%, VVOS is in the better half of the industry, outperforming 78.00% of the companies in the same industry.
VVOS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VVOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
2. Health
2.1 Basic Checks
VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVOS has been increased compared to 1 year ago.
VVOS has more shares outstanding than it did 5 years ago.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -6.80, we must say that VVOS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VVOS (-6.80) is worse than 90.00% of its industry peers.
A Debt/Equity ratio of 1.72 is on the high side and indicates that VVOS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.72, VVOS is doing worse than 72.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.8 |
ROIC/WACCN/A
WACC9.19%
2.3 Liquidity
VVOS has a Current Ratio of 1.05. This is a normal value and indicates that VVOS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VVOS (1.05) is worse than 70.00% of its industry peers.
A Quick Ratio of 1.05 indicates that VVOS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.05, VVOS is doing worse than 67.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 1.05 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 75.65% over the past year.
The Revenue has been growing slightly by 2.66% in the past year.
VVOS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.70% yearly.
EPS 1Y (TTM)75.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)2.66%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%-5.77%
3.2 Future
The Earnings Per Share is expected to grow by 29.04% on average over the next years. This is a very strong growth
Based on estimates for the next years, VVOS will show a very strong growth in Revenue. The Revenue will grow by 40.63% on average per year.
EPS Next Y36.91%
EPS Next 2Y29.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.79%
Revenue Next 2Y40.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VVOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVOS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VVOS's earnings are expected to grow with 29.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.04%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VVOS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.36
-0.11 (-4.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners10.57%
Inst Owner Change-5.73%
Ins Owners19.63%
Ins Owner Change0%
Market Cap17.70M
Revenue(TTM)14.39M
Net Income(TTM)-14320000
Analysts80
Price Target5.36 (127.12%)
Short Float %5.53%
Short Ratio0.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.18%
Min EPS beat(2)-40.06%
Max EPS beat(2)-10.29%
EPS beat(4)2
Avg EPS beat(4)3.97%
Min EPS beat(4)-40.06%
Max EPS beat(4)35.71%
EPS beat(8)4
Avg EPS beat(8)2.01%
EPS beat(12)6
Avg EPS beat(12)3.75%
EPS beat(16)7
Avg EPS beat(16)-2.48%
Revenue beat(2)0
Avg Revenue beat(2)-10.17%
Min Revenue beat(2)-19.36%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-8.46%
Min Revenue beat(4)-19.36%
Max Revenue beat(4)-0.98%
Revenue beat(8)1
Avg Revenue beat(8)-6.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-58.06%
EPS NY rev (1m)-7.78%
EPS NY rev (3m)-16.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)16.39%
Revenue NY rev (1m)2.93%
Revenue NY rev (3m)15.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.86 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.68
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS1.92
BVpS0.61
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -312.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.93% | ||
| FCFM | N/A |
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
F-Score1
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 161.71% | ||
| Cap/Sales | 8.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | -6.8 |
F-Score1
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)121.46%
Cap/Depr(5y)141.96%
Cap/Sales(3y)5.11%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y36.91%
EPS Next 2Y29.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.66%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%-5.77%
Revenue Next Year15.79%
Revenue Next 2Y40.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.4%
OCF growth 3YN/A
OCF growth 5YN/A
VIVOS THERAPEUTICS INC / VVOS FAQ
What is the ChartMill fundamental rating of VIVOS THERAPEUTICS INC (VVOS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VVOS.
What is the valuation status of VIVOS THERAPEUTICS INC (VVOS) stock?
ChartMill assigns a valuation rating of 1 / 10 to VIVOS THERAPEUTICS INC (VVOS). This can be considered as Overvalued.
Can you provide the profitability details for VIVOS THERAPEUTICS INC?
VIVOS THERAPEUTICS INC (VVOS) has a profitability rating of 1 / 10.